DataMEDS AI enters ATM sales agreement for up to $10,003,649 of common stock
On November 16, 2026, DataMEDS AI, Inc. entered into an at-the-market sales agreement with Dawson James Securities, Inc. permitting the company to offer and sell from time to time up to $10,003,649 of common stock, par value $0.0001 per share. The company will pay the sales agent a fixed commission rate of 3.0% of aggregate gross proceeds, and the company is not obligated to make any sales under the agreement. Shares will be sold under the company's effective Form S-3 shelf registration statement (File No. 333-2...
Key takeaways
Offering size: The ATM program permits sales of up to $10,003,649 of DataMEDS AI common stock, par value $0.0001 per share.
Sales agent and fees: Dawson James Securities, Inc. is the sales agent and will receive a fixed 3.0% commission on aggregate gross proceeds; the company also reimburses certain sales agent expenses, capped at $75,000 prior to execution and $10,000 per fiscal year for post-execution bring-down due diligence.
No obligation to sell: The company is not obligated to make any sales and may designate a minimum price below which the sales agent may not sell.
Termination: Either party may terminate the agreement on ten days' prior notice, and the agreement automatically terminates upon the earlier of the sale of all Placement Shares and expiration of the registration statement on the third anniversary of its initial effective date.
Registration: Shares will be sold under the Form S-3 shelf registration statement (File No. 333-295078), filed April 15, 2026 and declared effective May 7, 2026, with a prospectus supplement dated November 16, 2026.
Sales methods and settlement: The sales agent may sell on The Nasdaq Capital Market or other markets and in negotiated transactions with the company's prior written consent; settlement occurs on the first Trading Day following each sale, with net proceeds paid in same day funds.
Other ATM programs: The company states it is not party to any other at-the-market or continuous equity transaction agreement with an agent or underwriter.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.